Disease-resistant pigs approved for sale in US
Pigs produced to be resistant to one of the world's most costly livestock diseases, using technology developed by the Roslin Institute at the University of Edinburgh, have been approved for sale to US consumers.
The US Food and Drug Administration (FDA) has approved the use of a gene-editing technology that makes pigs resistant to porcine reproductive and respiratory syndrome (PRRS) on animals destinated for the US food supply chain.
This landmark approval for animal genetics company Genus, following years of development, aims to tackle the challenge of a disease that is endemic to most pig-producing regions.
The infection, which causes fever, respiratory distress, and premature births, costs industry approximately $2.5 billion (£1.75 billion) each year in lost revenue in the US and Europe alone.
The approval follows years of collaboration with the FDA and is a significant step on the pathway to commercialisation of gene-edited pigs in the US and other international markets.
Gene-edited pigs
Researchers at the University of Edinburgh's Roslin Institute focused their efforts on the CD163 gene in pigs.
This gene produces a receptor on the surface of cells, which the PRRS virus uses to cause infection.
Experts removed a small section of this gene, focusing on the section of the receptor that the virus attaches to, leaving the rest of the molecule intact.
Supported by Edinburgh Innovations (EI), the University of Edinburgh's commercialisation service, the team collaborated with Genus, which also licensed novel technologies from other institutions, to produce pigs with the specific DNA change.
The resulting pigs do not become infected with the virus, and the animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.
Prof. Bruce Whitelaw of the Roslin Institute said: 'We are delighted to see the PRRS-resistant pig gene-edit approved for use – this is a milestone in the use of gene editing in livestock, and a landmark moment for the livestock industry towards managing a global disease that causes devastating losses.'
CEO of Genus, Jorgen Kokke added: 'FDA approval is a fantastic achievement for Genus PIC and represents a major step towards US commercialisation.
'We will now continue to pursue regulatory approvals in other international jurisdictions with a focus on key US export markets.'
EI's head of business development at the University of Edinburgh's College of Medicine and Vet Medicine, Dr. Susan Bodie added: 'This is a very exciting development in translating cutting edge research into a major solution for the food production industry.
'Gene editing – making targeted changes to DNA in a lab – allows scientists to rapidly introduce beneficial traits in plants and animals, which can take decades to achieve through traditional breeding programmes.
'EI is proud to support Roslin Institute researchers to work with industry on pioneering world-changing animal bioscience like this.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
2 days ago
- Irish Times
US health secretary Kennedy guts vaccine advisory committee
US health secretary Robert F Kennedy Jr has fired all 17 members of a panel of vaccine experts and is in the process of replacing them, his department said on Monday, drawing protest from many scientists. The move is the most far-reaching in a series of actions by Mr Kennedy, a long-time vaccine sceptic, to reshape US regulation of vaccines, food and medicine. Scientists and experts said the changes to the US Centres for Disease Control and Prevention vaccine advisory panel, which recommends how vaccines are used and by whom, would undermine public confidence in health agencies. Mr Kennedy promised the move would raise public confidence. READ MORE 'Today we are prioritising the restoration of public trust above any specific pro- or anti-vaccine agenda,' he said in a statement. Mr Kennedy has for years sowed doubt about the safety and efficacy of vaccines, but he pledged to maintain the country's existing vaccine standards to secure his appointment in US president Donald Trump's administration. The Food and Drug Administration (FDA), which is overseen by his department, has approved a number of vaccines during his tenure despite concerns over his stances. Even so, at least one senior Republican member of Congress expressed doubts about the changes in the panel. Mr Kennedy said the advisory panel is rife with conflicts and has never turned down a vaccine, even though the decision to approve vaccines rests with the FDA. 'That's a tragedy,' said former FDA chief scientist Jesse Goodman. 'This is a highly professional group of scientists and physicians and others ... It's the kind of political meddling that will reduce confidence rather than increase confidence.' The Pharmaceutical Research and Manufacturers of America called Mr Kennedy's action concerning for public health. 'Upending the [panel's] membership increases uncertainty and vaccine scepticism, undermining the health gains achieved through vaccination,' the industry body said in a statement. Shares of vaccine makers Moderna and BioNTech fell more than 1 per cent, while Pfizer was down marginally in extended trading on Monday. Mr Kennedy said most panel members receive funding from drug companies, although members are required to declare any potential or perceived conflicts of interest that arise in the course of their tenure and any relevant business interests, positions of authority or other connections with organisations relevant to the committee's work. Mr Kennedy provided no specific evidence of industry conflicts of interest among departing panel members. All 17 panel members were appointed under former president Joe Biden's administration, including 13 in 2024. Without their removal, the Trump administration would not have been able to choose a majority of the committee until 2028. – Reuters
RTÉ News
27-05-2025
- RTÉ News
Poolbeg Pharma gets FDA support for POLB 001 drug
Biopharmaceutical company Poolbeg Pharma said the US Food and Drug Administration has granted Orphan Drug Designation (ODD) to its POLB 001 product as an oral preventative therapy for Cytokine Release Syndrome (CRS). Cancer immunotherapy-induced CRS is a severe side-effect that occurs in more than 70% of patients and which may lead to multi-organ failure and death. There are currently no approved preventative therapies for CRS. Poolbeg focusses on the development of innovative medicines to address unmet medical needs and its programmes target large addressable markets including, cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity. The company said the FDA grants orphan status to support the development of medicines for rare disorders affecting less than 200,000 people in the US. It provides Poolbeg with clinical development and commercialisation benefits including the potential for a seven-year period of US market exclusivity after regulatory approval of POLB 001, potential waiver exemption of Prescription Drug User Fee Act application fees and the potential for tax credits for qualifying clinical trials. Poolbeg expects the first patient to be dosed in its proposed Phase 2a in the second half of this year, with interim analysis expected in the first half of 2026 and Phase 2a topline data in the second half of 2026. Jeremy Skillington, the chief executive of Poolbeg Pharma, said that POLB 001 is potentially a breakthrough, orally delivered, preventative therapy for cancer immunotherapy-induced CRS which could significantly impact patients' lives. "We were delighted to receive Orphan Drug Designation from the FDA, which is a significant development for Poolbeg and for POLB 001, one that we believe will enhance the commercial appeal for prospective partners and help bring POLB 001 to the market faster," he said. "If approved, we believe POLB 001 has the potential to improve quality of life for patients, reduce pressure on healthcare systems, and expand access to cancer immunotherapies," the CEO added.
Irish Times
27-05-2025
- Irish Times
Poolbeg Pharma treatment gets FDA backing
The US Food and Drug Administration (FDA) has granted orphan drug designation to Poolbeg's preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The treatment, named POLB 001, is an oral preventative therapy to treat inflammation in blood and tissues. CRS is a severe side-effect that occurs in more than 70 per cent of patients, leading to severe side-effects or death. Cytokines can sweep throughout the body and cause tissue damage and shut down circulation and other essential organs. Orphan status is granted by the FDA for to support the development of treatments for rare disorders that affect under 200,000 people in the US, and makes the development of the drug less risky for Poolbeg, with the potential for seven-year period of US market exclusivity following approval of the treatment, waiver exemption of some fees and tax credits for qualified clinical trials. READ MORE 'POLB 001 is potentially a breakthrough, orally delivered, preventative therapy for cancer immunotherapy-induced CRS which could significantly impact patients' lives,' said Poolbeg chief executive Jeremy Skillington. 'We were delighted to receive Orphan Drug Designation from the FDA, which is a significant development for Poolbeg and for POLB 001, one that we believe will enhance the commercial appeal for prospective partners and help bring POLB 001 to the market faster. If approved, we believe POLB 001 has the potential to improve quality of life for patients, reduce pressure on healthcare systems, and expand access to cancer immunotherapies.' There are currently no approved preventative therapies for CRS. The first patients are expected to get the drug in the second half of the year, as part of Poolbeg's Phase 2a trial. 'Orphan Drug Designation from the FDA underscores the urgency and importance of developing innovative therapies for this critical unmet medical need,' said Professor Brendan Buckley, Poolbeg non-executive director and a member of the scientific advisory board. 'We look forward to progressing POLB 001 in our upcoming Phase 2a clinical trial and working closely with prospective partners and regulatory agencies to bring this potential therapy to patients as quickly as possible.'
